Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan

BACKGROUND: Lenvatinib demonstrated a treatment effect on overall survival by the statistical confirmation of non-inferiority to sorafenib for the first-line treatment of uHCC. The objective of this study was to evaluate the cost-effectiveness of lenvatinib compared with sorafenib for patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Masahiro, Kudo, Masatoshi, Izumi, Namiki, Kaneko, Shuichi, Azuma, Mie, Copher, Ronda, Meier, Genevieve, Pan, Janice, Ishii, Mika, Ikeda, Shunya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2019
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536477/
https://www.ncbi.nlm.nih.gov/pubmed/30788569
http://dx.doi.org/10.1007/s00535-019-01554-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536477/
https://www.ncbi.nlm.nih.gov/pubmed/30788569
http://dx.doi.org/10.1007/s00535-019-01554-0

Ejemplares similares